RPS6 and breast carcinoma: Consistent with this observation, the inhibition of miR-129-5p in the trastuzumab-susceptible breast cancer cell line, SK-BR-3, induced trastuzumab resistance, whereas concurrent treatment of RPS6-siRNA abolished this resistance.